The University of Houston's nursing program has received a significant gift to address the nursing industry's workforce shortage. Photo via UH.edu

A University of Houston alumnus and his wife have donated a historic gift to strengthen nursing education and research at his alma mater.

Andy and Barbara Gessner's $20 million gift to the UH College of Nursing was announced this week during National Nurses Week. The contribution will go toward scholarships and fellowships for students, as well as support programming and research to address the shortage of nurses in the workforce. The college has been renamed in honor of the gift to the Andy and Barbara Gessner College of Nursing.

The Gessners’ support of the College of Nursing is inspired by the many caring and giving nurses they know, including their late mothers, who were both nurses. Gertrude Smith Gessner and Mildred Roberson Pottenger dedicated their lives to delivering compassionate health care to their patients and serving their communities with distinction.

“We believe in nurses and we need more of them right now,” Andy Gessner, whose mother and mother-in-law were both nurses, says in a news release. “We’re all going to need a nurse at some time in our lives, and there's just not enough in the workforce or being educated for the future. The primary intent of our gift is to make more nurses available when we need them, now and in the future.”

By 2025, according to the Bureau of Labor Statistics, there will be a shortage of almost 200,000 registered nurses and a rise in demand of 12 percent between now and 2029.

“The silver tsunami is coming,” says Barbara Gessner in the release. “We are certainly going to need more nurses as the population gets older, so the medical profession will be put to the test. It's always been an honorable profession, and we believe in that tender, compassionate care that nurses provide.”

The donation will create three endowed professorships, two of the which will be matched one-to-one as part of the University’s “$100 Million Challenge” for chairs and professorships. Additional endowments funded by the gift, according to UH, will go toward research, nursing education, clinical learning, scholarships, graduate student fellowships, adjunct faculty support and and more.

“Our college of Nursing has been a leader in preparing highly skilled nurses for the workforce, and this comprehensive gift from Andy and Barbara Gessner will take it to the next level,” says UH President Renu Khator. “We are forever grateful to the Gessners for their vision, commitment and passion for nursing education so that we can educate more nurses who will make a positive impact on the lives of patients and in the health care industry.”

Kathryn Tart is the founding dean of the Gessner College of Nursing, and she believes the gift will have a significant impact on the university as well as the industry as a whole.

“This gift will have a lasting impact on the nursing profession and our great city, state and beyond for many years to come,” she says. “We will be able to attract more top faculty and students and increase our research endeavors to further the University’s mission of becoming a top 50 public university. We are so grateful to the Gessners for their support and vision to address the severe nursing shortage.”

In 2019, the Gessner Family Nursing Scholarship was established. To date, the scholarship has provided full tuition to 19 students in the Traditional BSN program.

“Our legacy will not be about what we did, it's what this gift will do,” says Andy Gessner. “We hope that in the coming years, the Gessner College of Nursing will be recognized for excellence and for creating more nurses.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers: Here's what it takes to spot a great new idea

houston voices

Having a “promotion focus” really does create a mental lens through which new ideas are more visible.

Key findings:

  • New ideas can be crucially important to businesses, driving innovation and preventing stagnation.
  • Recognizing those ideas, though, isn’t always easy.
  • Nurturing what is known as “promotion focus” can help managers spot fresh ideas.

Whenever the late surgeon Michael DeBakey opened a human chest, he drew on a lifetime of resources: the conviction that heart surgery could and should be vastly improved, the skill to venture beyond medicine’s known horizons and the vision to recognize new ideas in everyone around him, no matter how little formal training they had.

Appreciating new ideas is the heartbeat of business as well as medicine. But innovation is surprisingly hard to recognize. In a pioneering 2017 article, Rice Business Professor Jing Zhou and her colleagues published their findings on the first-ever study of the traits and environments that allow leaders to recognize new ideas.

Recent decades have produced a surge of research looking at how and when employees generate fresh ideas. But almost nothing has been written on another crucial part of workplace creativity: a leader’s ability to appreciate new thinking when she sees it.

Novelty, after all, is what drives company differentiation and competitiveness. Work that springs from new concepts sparks more investigation than work based on worn, already established thought. Companies invest millions to recruit and pay star creatives.

Yet not every leader can spot a fresh idea, and not every workplace brings out that kind of discernment. In four separate studies, Zhou and her coauthors examined exactly what it takes to see a glittering new idea wherever it appears. Their work sets the stage for an entirely new field of future research.

First, though, the team had to define their key terms. “Novelty recognition” is the ability to spot a new idea when someone else presents it. “Promotion focus,” previous research has shown, is a comfort level with new experiences that evokes feelings of adventure and excitement. “Prevention focus” is the opposite trait: the tendency to associate new ideas with danger, and respond to them with caution.

But does having “promotion focus” as opposed to “prevention focus” color the ability to see novelty? To find out, Zhou’s team came up with an ingenious test, artificially inducing these two perspectives through a series of exercises. First, they told 92 undergraduate participants that they would be asked to perform a set of unrelated tasks. Then the subjects guided a fictional mouse through two pencil and paper maze exercises.

While one exercise showed a piece of cheese awaiting the mouse at the end of the maze (the promise of a reward), the other maze depicted a menacing owl nearby (motivation to flee).

Once the participants had traced their way through the mazes with pencils, they were asked to rate the novelty of 33 pictures — nine drawings of space aliens and 24 unrelated images. The students who were prepped to feel an adventurous promotion focus by seeking a reward were much better at spotting the new or different details among these images than the students who’d been cued to have a prevention focus by fleeing a threat.

The conclusion: a promotion focus really does create a mental lens through which new ideas are more visible.

Zhou’s team followed this study with three additional studies, including one that surveyed 44 human resource managers from a variety of companies. For this study, independent coders rated the mission statements of each firm, assessing their cultures as “innovative” or “not innovative.” The HR managers then evaluated a set of written practices — three that had been in use for years, and three new ones that relied on recent technology. The managers from the innovative companies were much better at rating the new HR practices for novelty and creativity. To recognize novelty, in other words, both interior and external environments make a difference.

The implications of the research are groundbreaking. The first ever done on this subject, it opens up a completely new research field with profound questions. Can promotion focus be created? How much of this trait is genetic, and how much based on natural temperament, culture, environment and life experience? Should promotion focus be cultivated in education? If so, what would be the impact? After all, there are important uses for prevention focus, such as corporate security and compliance. Meanwhile, how can workplaces be organized to bring out the best in both kinds of focus?

Leaders eager to put Zhou’s findings to use right away, meanwhile, might look to the real-world model of Michael DeBakey. Practice viewing new ideas as adventures, seek workplaces that actively push innovation and, above all, cultivate the view that every coworker, high or low, is a potential source of glittering new ideas.

---

This article originally appeared on Rice Business Wisdom.

Jing Zhou is the Mary Gibbs Jones Professor of Management and Psychology in Organizational Behavior at the Jones Graduate School of Business of Rice University. Zhou, J., Wang, X., Song, J., & Wu, J. (2017). "Is it new? Personal and contextual influences on perceptions of novelty and creativity." Journal of Applied Psychology, 102(2): 180-202.

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”